The information highlighted (if any) are the most recent updates for this brand.
Irritability associated with autistic disorder.
Pediatric Patients 6-17 years: 5-15 mg daily. The dosage of Abilify Oral Solution should be individualized according to tolerability and response. Dosing should be initialized at 2 mg daily. The dose should be increased to 5 mg daily with subsequent increases to 10 or 15 mg daily, if needed. Dose adjustments of up to 5 mg daily should occur gradually at intervals of no less than 1 week.
Treatment should be symptomatic and supportive eg, adequate airway maintenance, cardiovascular monitoring and close medical supervision. Activated charcoal reduces serum concentration.
Hypersensitivity to aripiprazole.
Clinical improvement may take several days to some weeks. Monitoring of the patient throughout this period is recommended. Reduce dose or discontinue if signs or symptoms of tardive dyskinesia appear. Discontinue if patient develops signs and symptoms indicative of neuroleptic malignant syndrome. Caution in patients with a history of seizure.
Effects on the Ability to Drive or Operate Machinery: Until individual patient response is established, caution is advised when driving or operating machines.
Use in pregnancy & lactation: Do not use in pregnancy unless the benefit outweighs the risk.
Breastfeeding is not advised during treatment.
Do not use in pregnancy unless the benefit outweighs the risk.
Breastfeeding is not advised during treatment.
Adverse events occurred in ≥10% of patients treated with Abilify Oral Solution are headache, nausea, vomiting, constipation, anxiety, insomnia, lightheadedness, somnolence, akathisia, dyspepsia, agitation.
Both CYP3A4 and CYP2D6 are responsible for Abilify Oral Solution metabolism. Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in Abilify Oral Solution clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine or paroxetine) can inhibit Abilify Oral Solution elimination and cause increased blood levels.
N05AX12 - aripiprazole ; Belongs to the class of other antipsychotics.
Abilify Oral Solution 1 mg/mL
150 mL x 1's (Rp512,250/botol)